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Abstract: Colorectal cancer continues to be an important public health concern, despite 
improvements in screening and better systemic chemotherapy. The integration of targeted 
therapies in the treatment of colon cancer has resulted in signiﬁ  cant improvements in efﬁ  cacy 
outcomes. Angiogenesis is important for tumor growth and metastasis and is an important target 
for new biological agents. Bevacizumab is a humanized recombinant antibody that prevents 
vascular endothelial growth factor (VEGF) receptor binding, and inhibits angiogenesis and tumor 
growth. The addition of bevacizumab to ﬂ  uoropyrimidine-based chemotherapy, with or without 
irinotecan or oxaliplatin, in both the ﬁ  rst- and second-line treatment of metastatic colorectal 
cancer, signiﬁ  cantly increased median progression-free survival and overall survival in select 
randomized phase III studies. Ongoing studies are evaluating the role of bevacizumab in the 
adjuvant treatment of colon cancer. Common toxicities associated with bevacizumab include 
hypertension, bleeding episodes, and thrombotic events. This review will focus on the inte-
gration of bevacizumab in the treatment paradigm of colon cancer and the management of its 
side effects.
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Introduction
Colorectal cancer (CRC) is the second leading cause of death in the US. An estimated 
148,810 cases of CRC are expected to occur in 2008, resulting in 49,960 deaths, almost 
10% of all cancer deaths.1 Overall, the 5-year survival for all patients has improved 
signiﬁ  cantly from 41% in 1950–54 to 66% in 1996–2004.2 Survival is still dependent 
on stage of disease, with the 5-year survival ranging from 85% to 90% in stage I 
disease to ≈10% for patients with stage IV disease.3,4
For several decades 5-ﬂ  uorouracil (FU)/leucovorin (LV)-based therapy was 
the mainstay of treatment of CRC. In the past decade, the outcome of patients with 
metastatic CRC has improved considerably with the advent of combination regimens 
of oxaliplatin or irinotecan and 5-FU/LV.5,6 The addition of irinotecan to a bolus 
or infusional regimen of 5-FU in combination with LV in the ﬁ  rst line setting has 
resulted in a median survival of 15 to 23 months.6–8 Infusional 5-FU/LV is clearly 
less toxic and slightly more efﬁ  cacious than bolus administration and hence has 
evolved to become the preferred regimen in combination with irinotecan (FOLFIRI) 
and oxaliplatin (FOLFOX). Most recently, the incorporation of monoclonal antibod-
ies that bind to vascular endothelial growth factor (VEGF) and to epidermal growth 
factor receptors (EGFR) into the current armamentarium has further widened the 
treatment options.9,10 Irrespective of the ﬁ  rst-line chemotherapy regimen used, 
when patients are exposed to all active cytotoxic drugs available against CRC an 
overall survival (OS) exceeding 2 years is currently achieved.11 In this review we 
will discuss the role of bevacizumab in the treatment of CRC and brieﬂ  y discuss its 
side effect proﬁ  le.OncoTargets and Therapy 2009:2 2
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VEGF pathway
Angiogenesis is a complex multistep process of new blood 
vessel formation and is considered critical for the growth of 
tumors.12 In 1971, Judah Folkman ﬁ  rst proposed that tumor 
angiogenesis could serve as a potential target for anticancer 
therapy.13 One of the major pathways involved in this process 
is the VEGF family of proteins and receptors.14,15 VEGF is 
a diffusible homodimeric glycoprotein produced by healthy 
and neoplastic cells and is a key promoter of angiogenesis 
under both physiological and pathological conditions, includ-
ing tumor progression.16
The VEGF family includes 6 members referred to as 
VEGF-A through VEGF-E and placental growth factor 
(PIGF). It is recognized that the major mediator of tumor 
angiogenesis is VEGF-A (referred to as VEGF henceforth 
in this review).17–19 VEGF ligands mediate their angiogenic 
effects mainly through 3 different cell membrane recep-
tors, VEGF R-1, -2 and -3.20–25 These receptors consist of 
an extracellular domain, a transmembrane domain and 
an intracellular tyrosine kinase domain. Binding of the 
ligand to the receptor induces the activation of intracel-
lular signaling transduction pathways that are involved 
in the regulation of cellular proliferation and survival, 
such as the raf/MEK, mTOR and PI3K pathways (see 
Figure 1). The neuropilins are a class of transmembrane 
proteins (NRP-1 and NRP-2) that lack tyrosine kinase 
activity but act as co receptors for the VEGF receptors, 
increasing their binding affinity.26–29 Most recently, alter-
native signaling pathways (notch-delta like ligand ) have 
been studied and appear to be important regulators in the 
angiogenesis pathway.
The expression of VEGF is increased in most human 
tumors (including CRC), with contributions from both 
malignant and host cells. Several studies have shown that 
VEGF levels correlate with increased micro vessel density, 
higher incidence of metastasis, decreased apoptotic index 
and poor OS of patients with CRC.30–34 Because VEGF and 
its receptors play a critical role in angiogenesis and tumor 
progression, initial work focused on the development of 
agents that speciﬁ  cally inhibit this pathway. Several pre-
clinical models demonstrated that monoclonal antibodies 
directed against VEGF inhibit tumor growth in mice.35,36 
In an experimental liver metastasis model, blocking VEGF 
with murine monoclonal antibody (A.4.6.1) showed reduc-
tion in the size and the number of liver metastasis in mice.37 
Preclinical models also showed a synergistic effect combin-
ing anti-VEGF antibodies with cytotoxic chemotherapy or 
radiation therapy.38–40
Bevacizumab is a recombinant, humanized, monoclonal 
antibody directed against the VEGF ligand (VEGF-A) and 
binds all isoforms of VEGF-A with high afﬁ  nity. In the ini-
tial phase 1 study of bevacizumab in patients with advanced 
cancer, bevacizumab was safely administered without dose-
limiting toxicity at doses ranging up to 10 mg/kg.41,42 Beva-
cizumab was well tolerated, and pharmacokinetic studies 
indicated that doses of    0.3 mg/kg had a half-life similar 
to that of other humanized antibodies. Bevacizumab showed 
a linear pharmacokinetic proﬁ  le and a terminal half-life of 
around 21 days. Subsequently several phase II studies were 
initiated with bevacizumab single agent or in combination 
with chemotherapy in the treatment of various solid tumors 
with promising results.43–46
Bevacizumab in the ﬁ  rst-line 
treatment of metastatic CRC
In colorectal cancer, two dosages of bevacizumab have been 
investigated after a randomized phase II study of high and 
low dose bevacizumab in combination with 5-FU/LV showed 
considerable improvement in efﬁ  cacy when compared to 
the 5-FU/LV control.47 One hundred and four previously 
untreated patients with measurable metastatic CRC were 
randomly assigned to one of three treatment groups: 5-FU 
(500 mg/m2) and LV (500 mg/m2) (weekly for 6 weeks of 
each 8-week cycle), 5-FU/LV plus bevacizumab (5 mg/kg 
once every 2 weeks), and 5-FU/LV plus bevacizumab 
(10 mg/kg once every 2 weeks). Response rates were higher 
in both bevacizumab arms: 17% for FU/LV alone, 40% for 
FU/LV/low-dose bevacizumab and 24% for FU/LV/ high-
dose bevacizumab. Furthermore, time to disease progression 
was longer in both bevacizumab arms: 5.2 months for FU/LV 
alone, 9.0 months for FU/LV/low-dose bevacizumab, and 
7.2 months with FU/LV/high-dose bevacizumab with a trend 
towards improved survival (Table 1). The major safety con-
cerns were gastrointestinal (GI) bleeding (0, 6% and 16%) 
and thrombosis (9%, 26% and 13%) seen in the 5-FU/LV, 
5-FU/LV with 5 mg/kg bevacizumab and 5-FU/LV with 
10 mg/kg bevacizumab, respectively.
Bevacizumab in combination
with irinotecan-based regimens
The clinical beneﬁ  t seen with the addition of bevacizumab 
to 5-FU/LV based chemotherapy in phase II studies was 
further studied in a pivotal phase 3 study.9 Patients were 
initially randomized in a 1:1:1 ratio to 6-week cycles of 
IFL (irinotecan 125 mg/m2, 5-FU 500 mg/m2 and LV 
20 mg/m2 once a week for 4 weeks plus bevacizumab OncoTargets and Therapy 2009:2 3
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5 mg/kg every 2 weeks), 6-week cycles of IFL plus placebo, 
or 8-week cycles of 5-FU (500 mg/m2) and LV (500 mg/m2) 
once a week for 6 weeks) plus bevacizumab (5 mg/kg). 
After 300 patients were randomized, an unblinded safety 
analysis found that the IFL plus bevacizumab regimen 
had an acceptable safety proﬁ  le, and randomization to the 
5-FU/LV plus bevacizumab arm was discontinued as per 
the pre-planned design. Compared with IFL alone, IFL plus 
bevacizumab improved the progression-free survival (PFS) 
from a median of 6.2 months to 10.6 months, the overall 
response rate from 34.8% to 44.8%, and the median OS from 
15.6 to 20.3 months. The clinical beneﬁ  t of bevacizumab was 
seen across all pre-speciﬁ  ed patient subgroups including age, 
performance status, location and number of metastatic sites. 
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Figure 1 The major mediator of tumor angiogenesis is the vascular endothelial growth factor (VEGF) family of growth factors.   The VEGF family binds to the VEGF receptors 
(VEGFR)-R1, VEGFR-2, VEGFR-3 tyrosine kinase as shown in ﬁ  gure. Neuropilin (NRP 1 and 2) are co-receptors for the VEGFRs and lack tyrosine kinase activity.   The binding 
of VEGF to the VEGF receptors results in activation of the intracellular pathways.   Activation of the PLC-PKC-raf kinase-MEK-mitogen activated protein kinase pathway results 
in increased cell proliferation. Activation of the phosphatidylinositol 3’-kinase (P13K), akt pathway leads to increased cell survival.OncoTargets and Therapy 2009:2 4
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On February 26, 2004 the FDA approved bevacizumab as a 
ﬁ  rst-line treatment in metastatic CRC.
Given the synergistic activity of bevacizumab when 
added to IFL or to 5-FU/LV, bevacizumab was incorpo-
rated into different schedules of irinotecan-based regimens 
(Table 2). The combination of bevacizumab and FOLFIRI 
was studied in two small phase II studies with good toler-
ability and efﬁ  cacy.48,49 These results were further explored 
in a number of phase III studies.
In the complex BICC-C trial, patients with previously 
untreated metastatic CRC were randomized to: infusional 
5-FU/LV with irinotecan, modified IFL (mIFL: bolus 
5-FU/LV/irinotecan given weekly × 2 every 3 weeks), or 
capecitabine with irinotecan. Patients were randomized fur-
ther to receive concurrent celecoxib or placebo in a double-
blind fashion. Upon approval of bevacizumab in the ﬁ  rst-line 
treatment of metastatic CRC in the US, the protocol was 
amended to add bevacizumab and to limit the randomization 
to FOLFIRI and mIFL arms with or without celecoxib. Study 
data presented in ASCO 2007 showed the bevacizumab plus 
FOLFIRI arm with a median PFS of 11.2 months, 1-year 
survival of 87% and a median OS of 28 months. The median 
OS of FOLFIRI plus bevacizumab compared favorably to 
mIFL plus bevacizumab (median, 19.2 months; p = 0.037). 
However, the data are limited by the small sample size 
(57 patients treated with FOLFIRI plus bevacizumab).50,51 
A phase IV study of ﬁ  rst-line bevacizumab plus FOLFIRI 
in patients with metastatic CRC (AVIRI study) lends further 
support to the integration of bevacizumab with FOLFIRI in 
the ﬁ  rst-line setting.52 A total of 209 patients were enrolled 
at 31 centers worldwide. Interim efﬁ  cacy results showed 
a median PFS of 11.1 months and a response rate (RR) of 
53.1%. Median OS data were not available at the time of 
this report.
Bevacizumab in combination
with oxaliplatin-based regimens
The landmark N 9741 study compared oxaliplatin plus 
infusional 5-FU/LV (FOLFOX) regimen to IFL and to IROX 
(irinotecan plus oxaliplatin combination). This study showed 
a statistically signiﬁ  cant improvement in time to progression 
(TTP) and OS for FOLFOX (oxaliplatin 85 mg/m2 on 
day 1 and bolus FU 400 mg/m2 plus LV 200 mg/m2 fol-
lowed by FU 600 mg/m2 in 22-hour infusions on days 
1 and 2 every 2 weeks) over IFL (irinotecan 125 mg/m2 
and bolus FU 500 mg/m2 plus LV 20 mg/m2 on days 1, 8, 
15 and 22 every 6 weeks ) and IROX (oxaliplatin 85 mg/m2 
and irinotecan 200 mg/m2 every 3 weeks) resulting in the 
Table 1 Initial phase II trials of bevacizumab in metastatic colorectal cancer
Phase II studies Chemotherapy regimen n Time to progression
(months)
Response rate Median survival
(months)
Kabbinavar et al47 5-FU/LV 36 5.2 6 (17%) 13.8
5-FU/LV + BV 5 mg/kg 35 9 14 (40%) 21.5
5-FU/LV + BV 10 mg/kg 33 7.2 8 (24%) 16.1
Kabbinavar et al57 5-FU/LV 105 5.5 15.2% 12.9
  5-FU/LV + BV 5 mg/kg 104 9.2 26% 16.6
Abbreviation: BV, bevacizumab.
Table 2 Selected randomized studies of bevacizumab in ﬁ  rst-line metastatic colorectal cancer 
Studies Phase Chemotherapy regimen n Time to progression 
(months)
Response rate (%) Median survival 
(months)
Hurwitz9 III IFL + BV 5 mg/kg 402 10.6 44.8 20.3
BICC-C8 III FOLFIRI + BV 5 mg/kg 57 11.2 57.9 28
mIFL + BV 5 mg/kg 60 8.3 53.3 19.2
AVIRI52 IV FOLFIRI + BV 5 mg/kg 209 11.1 44 NRa
TREE-254 II FOLFOX + BV 5 mg/kg 71 9.9 52 26.1
bFOL + BV 5 mg/kg 70 8.3 39 20.4
CapeOX + BV 5 mg/kg 72 10.3 46 24.6
N1696655 III FOLFOX or XELOX + BV 5 mg/kg 699 9.4 49 21.3
aNR, not reported.OncoTargets and Therapy 2009:2 5
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approval of  FOLFOX chemotherapy in the ﬁ  rst-line treatment 
of MCRC.53 Subsequent studies investigated if the addition of 
bevacizumab to oxaliplatin-based regimens improve patient 
outcome. In the TREE-2 trial, 213 previously untreated 
patients with metastatic CRC were randomly assigned to 
bevacizumab (5 mg/kg every 2 weeks) and one of the three 
different oxaliplatin and 5-FU-containing regimens used in 
the TREE 1 trial – FOLFOX (mFOLFOX6 – bolus and infu-
sion ﬂ  uorouracil [FU] and leucovorin [LV] with oxaliplatin), 
oxaliplatin plus bolus 5-FU/LV (bFOL), or capecitabine 
plus oxaliplatin (CapeOx).54 While the bFOL arm was sig-
niﬁ  cantly less active than FOLFOX, CapeOx and FOLFOX 
showed similar activity. Bevacizumab signiﬁ  cantly improved 
the response rates of all of the regimens. The bevacizumab-
containing arms, combined, resulted in a median OS of 
23.7 months. This compared favorably with the median OS of 
18.2 months for the combined non-bevacizumab-containing 
groups on the TREE-1 study.
However, a large randomized phase III trial, NO16966, 
failed to show an advantage for the addition of bevacizumab 
to oxaliplatin-based ﬁ  rst-line treatment in term of RR or OS, 
although PFS was marginally improved.55 The study random-
ized 1,400 patients with metastatic CRC to receive ﬁ  rst-line 
FOLFOX4 versus capecitabine plus oxaliplatin (XELOX), 
with further randomization to bevacizumab or placebo. 
Bevacizumab was administered at 5 mg/kg intravenously 
every 2 weeks on the FOLFOX regimen and at 7.5 mg/kg 
every 3  weeks on the XELOX regimen. Median PFS was 
9.4 months in the bevacizumab arm compared with 8 months 
in the non-bevacizumab arm (HR = 0.83, p = 0.0023). 
However, unlike prior phase III bevacizumab studies, no 
beneﬁ  t was documented in OS (21.3 for the bevacizumab arm 
versus 19.9 months for the placebo arms) and RR (38% on 
both arms) with the addition of bevacizumab.9,56 This study 
was plagued by a high rate of unjustiﬁ  ed discontinuation of 
study treatment because of toxicity concerns despite lack 
of progressive disease. In fact, treatment was discontinued 
secondary to progressive disease only in 29% of patients 
with bevacizumab compared with 47% in the placebo 
groups. The duration of treatment with bevacizumab in the 
initial IFL with and without bevacizumab pivotal study was 
2.8 months longer compared with NO16966, likely due to the 
lack of dose-limiting neuropathy with IFL treatment.9 When 
NO16966 was analyzed using the pre-speciﬁ  ed secondary 
analysis of on-treatment PFS (patients who progressed or 
died within 28 days from the last dose of any component 
of study treatment), the median on treatment PFS was 
10.4 months versus 7.9 months, favoring the bevacizumab 
arm (HR 0.63; 97.5% CI, 0.52–0.75; p   0.001). Despite the 
fact that early bevacizumab discontinuation may explain the 
limited beneﬁ  t in terms of PFS and lack of OS advantage, it 
does not explain the lack of beneﬁ  t in terms of RR, a ﬁ  nding 
consistently seen in previous studies with bevacizumab.9,54,56 
In prior trials of bevacizumab in metastatic CRC in the ﬁ  rst-
line setting, RR increased by more than  10%, in comparison 
with the non-bevacizumab arms.9,56,57 Similarly, the addition 
of bevacizumab in the second-line setting to FOLFOX-4 
demonstrated a 13% improvement in RR compared with 
FOLFOX-4 alone.
Currently none of the phase III studies have evalu-
ated the value of bevacizumab in combination with the 
stop-and-go approach used with oxaliplatin-based regi-
mens.58 The CONcepT trial evaluated a standard FOLFOX 
(mFOLFOX7 – oxali 85 mg/m2, LV 200 mg/m2, 5FU 
2,400 mg/m2 × 46 hours) plus bevacizumab regimen versus 
a stop-and-go FOLFOX plus bevacizumab approach with or 
without intravenous calcium /magnesium supplementation.59 
The study was prematurely closed due to initial efﬁ  cacy con-
cerns in the calcium/magnesium arms. The ﬁ  nal analysis of 
the initial cohort of patients (n = 140) showed a higher time 
to treatment failure (TTF) (5.6 versus 4.2 months) without 
compromising PFS (12 versus 7.3 months), favoring patients 
in the stop-and-go schedule with bevacizumab. These data 
support the feasibility of a stop-and-go approach with 
FOLFOX-based regimens and suggest the superiority of 
such an approach over the administration of FOLFOX until 
toxicity or progression when combined with bevacizumab.
Bevacizumab plus FOLFIRI versus 
bevacizumab plus FOLFOX
Currently there are no randomized phase III studies which 
compare FOLFOX plus bevacizumab versus FOLFIRI plus 
bevacizumab. Results from the First BEAT trial, a large inter-
national community-based prospective observational study 
which enrolled 1,965 patients to evaluate the safety and efﬁ  -
cacy proﬁ  le of bevacizumab when combined with a variety 
of ﬁ  rst-line chemotherapy regimens in a general patient 
population with metastatic CRC, were presented at ASCO 
2008.60 Most commonly used regimens in combination with 
bevacizumab included FOLFOX (29%), FOLFIRI (26%), 
XELOX (18%) and 5-FU/capecitabine monotherapy (15%). 
The overall median PFS was 10.8 months and did not show 
major differences in PFS between the different combination 
therapy regimens. Overall survival was 22.7 months, with 
no major differences between the FOLFOX and FOLFIRI 
regimens (25.9 versus 23.7 months).OncoTargets and Therapy 2009:2 6
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Currently the integration of bevacizumab in the ﬁ  rst-line 
treatment of metastatic CRC irrespective of which ﬁ  rst-line 
regimen is chosen should be strongly considered. This is now 
supported not only by prospective randomized studies but 
also by large observational studies showing PFS in excess 
of 10.5 months for bevacizumab plus FOLFOX, XELOX, or 
FOLFIRI and in excess of 9 months for bevacizumab plus a 
ﬂ  uoropyrimidine monotherapy.
Bevacizumab in the treatment
of metastatic CRC in the second-
line setting
In general, bevacizumab should be integrated with ﬁ  rst-line 
chemotherapy in patients with metastatic CRC. In the 
case of major contraindications for bevacizumab, such as 
severe vascular disease or prior arterial thrombotic events, 
one should make a case for avoiding bevacizumab therapy 
during all lines of treatment.
In the event a bevacizumab-naïve patient fails ﬁ  rst-line 
chemotherapy, bevacizumab should be strongly considered in 
the setting of 5-FU based combination therapy in the second-
line setting. Supporting evidence comes from ECOG 3200, 
a phase III study randomizing patients to FOLFOX-4 plus 
bevacizumab versus FOLFOX-4 in patients who progressed 
after ﬁ  rst-line irinotecan, 5-FU and leucovorin.56 The beva-
cizumab arm was associated with a superior response rate 
(21.8% versus 9.2%), median PFS (7.2 versus 4.8 months), 
and median OS (12.9 versus 10.8 months). No other 
randomized phase III studies investigated bevacizumab after 
failure of a non-bevacizumab-containing regimen. However, 
it is generally agreed, based on synergy with 5-FU, that 
bevacizumab should be considered in combination with 
FOLFIRI in patients who previously failed FOLFOX without 
bevacizumab.
The continuation of bevacizumab beyond ﬁ  rst-line pro-
gression on bevacizumab-based regimens is controversial. 
Retrospective analysis of the large observational BRiTE 
study registry suggests a role for the continuation of beva-
cizumab.61 In this study, 1953 patients received ﬁ  rst-line 
bevacizumab-based chemotherapy, 1,192 patients progressed 
and received second-line chemotherapy. The use of second-
line bevacizumab as well as the choice of chemotherapy 
was at the individual investigator’s discretion. Patients who 
continued on bevacizumab along with their cytotoxic second-
line treatment experienced a signiﬁ  cant improvement in their 
median OS, whether computed from the start of ﬁ  rst- or 
second-line therapy (31.8 versus 19.9 months, 19.2 versus 
9.5 months, respectively). The lack of randomized design and 
the likely selection bias of good performance status in the 
bevacizumab continuation arm lead to caution in the inter-
pretation of these results. The ongoing SWOG S0600/iBET 
study is currently randomizing patients who progressed on 
FOLFOX plus bevacizumab to irinotecan (with or without 
5-FU)/ cetuximab with or with bevacizumab. This study will 
hopefully determine the value of bevacizumab continuation 
after bevacizumab-ﬁ  rst line progression.
Bevacizumab in the treatment
of metastatic CRC in the third-line 
setting
The role of bevacizumab in combination with bolus or 
infusional 5-FU/LV in the third line was studied in a mul-
ticenter phase II trial of 350 patients who had failed both 
irinotecan- and oxaliplatin based chemotherapy regimens.62 
A planned efﬁ  cacy analysis was done on the ﬁ  rst 100 enrolled 
patients. The objective response rate was 4% based on the 
investigator’s assessment, and 1% based upon an independent 
review. Median PFS and OS were 3.5 and 9 months, respec-
tively. Based on this study, the use of third-line 5-FU/LV 
plus bevacizumab in chemoresistant patients is considered 
an ineffective treatment.
Combining bevacizumab with other 
biological agents: dual inhibition
of VEGF and EGFR
Cetuximab and panitumumab are anti-EGFR monoclonal 
antibodies with proven efﬁ  cacy in metastatic CRC. Cetux-
imab, a IgG1 chimeric monoclonal antibody, is approved as 
a single agent or in combination with irinotecan in irinote-
can-resistant metastatic CRC.63 Panitumumab, a human IgG1 
monoclonal antibody, is approved as monotherapy in patients 
with metastatic CRC that have failed standard chemotherapy.64 
Preclinical models have showed a synergistic effect with dual 
targeting of anti VEGF and EGFR pathways.65–67 The combi-
nations of the above monoclonal antibodies with bevacizumab 
have been studied in metastatic CRC.
The BOND-2 study is a randomized phase II trial 
comparing cetuximab plus bevacizumab (CB) with and 
without irinotecan (CBI) in 83 patients with irinotecan- and 
oxaliplatin-refractory but bevacizumab-naïve metastatic 
CRC.68 The CBI arm had a 37% response rate, TTP of 
7.9 months, and OS of 14.5 months; the biologic-alone arm 
of CB was also active, with a 20% response rate, TTP of 
5.6 months, and OS of 11.4 months. The toxicity pattern 
seemed to be similar to that which would be expected from OncoTargets and Therapy 2009:2 7
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the two agents given alone. However these results seem to be 
in conﬂ  ict with the subsequent PACCE and CAIRO2 trials 
in the ﬁ  rst-line treatment of metastatic CRC.
The PACCE study investigated the integration of pani-
tumumab in the ﬁ  rst-line treatment of metastatic CRC in 
combination with standard combination chemotherapy. 
Patients were treated at their physician’s choice with a com-
bination of FOLFOX plus bevacizumab or FOLFIRI plus 
bevacizumab and were randomized to receive panitumumab 
or nothing in addition to the standard selected therapy. 
A preplanned efﬁ  cacy analysis, disappointingly, showed 
that the dual biological combination arm had a shorter PFS 
and increased toxicity leading to study discontunuation.69,70 
Similarly, results from the CAIRO II study, a randomized 
study of capecitabine/oxaliplatin plus bevacizumab with or 
without cetuximab was presented at ASCO 2008. Again, the 
arm including both cetuximab and bevacizumab showed a 
signiﬁ  cant decrease in PFS compared to the control arm. 
However, besides skin toxicity and a modest increase in 
diarrhea, no added toxicity was seen with the addition 
of cetuximab.71 Of interest, neither the PACCE nor the 
CAIRO 2 studies showed an advantage to adding anti-EGFR 
inhibitors to bevacizumab-based combination in KRAS 
wild type patients, a population well known to beneﬁ  t from 
cetuximab therapy. Furthermore, the detrimental effects 
from the addition of anti-EGFR therapy were limited to the 
KRAS mutant population.71–73
Currently, the combination of anti-EGFR and anti-VEGF 
antibody therapy with chemotherapy in metastatic CRC 
cancer is contraindicated outside a clinical trial setting. 
CALBG 80405 continues to investigate the combination of 
FOLFOX or FOLFIRI with cetuximab, or bevacizumab, or 
cetuximab plus bevacizumab; however, with an amendment 
to limit accrual to KRAS wild type population.
Role of bevacizumab
in the adjuvant setting
The successful integration of bevacizumab in metastatic 
CRC paved the way for several adjuvant randomized 
studies in CRC in the US and Europe. Table 3 lists some 
of the trials that completed accrual or where accrual is 
ongoing.74–78
The initial safety data on bevacizumab given in conjunc-
tion with modiﬁ  ed combination ﬂ  uorouracil and leucovorin 
and oxaliplatin (mFOLFOX6) as postoperative adjuvant ther-
apy for patients with stage II or stage III colorectal cancer was 
presented at ASCO 2008.79 All wound complications seen 
in the study were grade 3, 1.7% in the bevacizumab versus 
0.3% in the control arm. Surgical intervention was required 
in only one case and in discontinuation of bevacizumab in 
half of the cases. Efﬁ  cacy data from randomized studies are 
still awaited. Until then, the integration of bevacizumab in 
combination with chemotherapy in the adjuvant setting is 
not recommended.
Bevacizumab in the elderly (more 
than 70 years) and in patients
with poor performance status
Treating the elderly CRC population, especially those with 
associated co-morbidities, is linked with signiﬁ  cant chal-
lenges. The majority of physicians tend to treat the elderly 
differently than younger patients, either by reducing dosages 
or by limiting the number of agents/combinations used in this 
population. The limited representation of elderly patients, 
particularly those   70 years, in large randomized clinical 
trials has resulted in a lack of clear identiﬁ  cation of an opti-
mal regimen in this subgroup of patients.6,7,53 Furthermore, 
with the increase in cardiovascular risk as individuals age, 
concern has naturally risen about the use of bevacizumab in 
this population.
The BRiTE study is a large (n = 1953) prospective mul-
ticenter study of ﬁ  rst-line metastatic CRC patients receiving 
a bevacizumab-based regimen with a follow up of more than 
3 years. The objective of the study was to describe the inci-
dence and timing of bevacizumab-related safety outcomes 
associated with long-time exposure to bevacizumab.80 Of 
1,953 patients in the BRiTE study, 896 were   65 years (533 
65–74, 363   75 and 161   80 years). Apart from a higher 
rate of arterial thrombotic events (ATE) in older patients, 
bevacizumab safety in the elderly was comparable to that 
in patients  65 years. Risk factors for developing ATEs 
included poor performance status and prior history of ATE. 
PFS in the elderly was similar to that in patients  65 years 
in BRiTE and other pivotal bevacizumab trials. Multivari-
ate analyses revealed that the lower median OS observed in 
older patients was attributed to poorer performance status 
and relative underexposure to active cytotoxic agents and 
post-progression therapy in the elderly.
Bevacizumab has also been investigated in patients with 
poor performance status (PS 1 or 2) and with advanced 
age (  65 years), who are not eligible for combination 
chemotherapy in a prospective randomized phase II study 
of 5-FU/LV with or without bevacizumab (Table 1).57 The 
bevacizumab arm showed a signiﬁ  cant beneﬁ  t in OS (16.6 
versus 12.1 months, p = 0.160), PFS (9.2 versus 5.5 months, 
p = 0.0002) and RR (26 versus 15.2%, p = 0.055).OncoTargets and Therapy 2009:2 8
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In summary, although limited data exist on the use of 
bevacizumab and chemotherapy in elderly patients with 
metastatic CRC, the available information suggests that in 
patients with an adequate performance status, the efﬁ  cacy 
of bevacizumab therapy is similar in older patients to that in 
the general population. In general, it is appropriate to treat 
patients based on their performance status, rather than just 
on their numerical age. There are currently no age-related 
eligibility criteria for treatment with bevacizumab.
Safety proﬁ  le and management
of adverse events associated
with bevacizumab
Early phase II and pivotal phase III studies in CRC utiliz-
ing bevacizumab have identiﬁ  ed hypertension (11%–32%), 
bleeding (mainly epistaxis; 30%–53%), proteinuria 
(10%–38%), ATE (1%–10%), gastrointestinal perforation 
(0.3%–2%), wound healing (1.3%–3.7%) as bevacizumab-
associated adverse events; these are detailed in Table 4. In 
most cases these side effects do not overlap with the toxicity 
associated with cytotoxic chemotherapy. As our clinical 
experience with bevacizumab accumulates, guidelines for 
managing the adverse events associated with bevacizumab 
are increasingly emerging.
Hypertension (HTN) and proteinuria
Initial phase II trials in metastatic CRC revealed a higher inci-
dence of HTN in patients treated with bevacizumab (grade 3 
16%).81 Subsequently, the pivotal phase III trial of IFL with 
or without bevacizumab in metastatic CRC showed similar 
results (all grade HTN: 22.4%; grade 3 HTN: 11%, and grade 
4 HTN: 0%–1%).9 The mechanism of bevacizumab-related 
HTN is unclear and has been attributed to possible alterations 
in the nitric oxide signaling pathway.82 VEGF inhibition by 
bevacizumab results in vasoconstriction of blood vessels with 
a resulting increase in blood pressure. Other mechanisms 
involving the renin-angiotensin system, endothelial dysfunc-
tion and capillary rarefaction have also been proposed.83,84 
There was initial suggestion of a correlation between the dose 
of bevacizumab and development of HTN and proteinuria.85 
A phase II study with bevacizumab dosed at 10 mg/kg was 
associated with a higher incidence of all grade HTN (28% 
versus 11%) compared with the standard dose of bevaci-
zumab (5 mg/kg).86 However, subsequent phase III studies 
which used 10 mg/kg of bevacizumab showed the incidence 
of HTN to be much lower (grade 3 HTN 5.2%).56
There are no clear guidelines for management of hyper-
tension in patients receiving bevacizumab. Hypertension 
can occur at any time after initiation of therapy with beva-
cizumab; hence blood pressure should be checked before 
each cycle of treatment. Patients should also be encouraged 
to monitor blood pressure at home. Patients who develop 
grade 2 HTN during bevacizumab therapy should be managed 
using standard oral antihypertensive therapy. Grade 3 HTN 
is managed by titrating up the patients’ anti-HTN medication 
or may require combination therapy with standard antihy-
pertensive medications (typically angiotensin-converting 
enzyme [ACE] inhibitors, diuretics, calcium channel or beta 
blockers). Although ACE inhibitors are attractive, especially 
with concomitant renal dysfunction or proteinuria, currently 
there is no data to determine the best antihypertensive 
agent available.87–89 In case of uncontrolled hypertension 
not responding to oral medications, bevacizumab should 
be suspended or permanently discontinued.87,88 Grade 4 
hypertension is an infrequent occurrence, and in patients 
who develop hypertensive crisis (grade 4) bevacizumab is 
permanently discontinued.87,88
Incidence of grade 3/4 proteinuria in recent phase III trials 
with bevacizumab in metastatic CRC have been reported in 
the range of less than 2%.9,55,90 The mechanism of proteinuria 
is not fully understood, but may be related to the effects of 
VEGF on the renal glomerular capillaries. It is advisable 
that patients receiving bevacizumab get a urinalysis (regular 
dipstick or microscopic) at baseline and throughout the treat-
ment. Patients with proteinuria   2+ on dipstick should have 
a 24-hour urine check for quantiﬁ  cation of protein. If patients 
develop   2 g/24 hours proteinuria, bevacizumab admin-
istration should be interrupted until proteinuria improves 
to   2 g/24 hours .Patients should be evaluated for ACE 
inhibitors or angiotensin-receptor blocker as initial treatment 
in case of development of proteinuria with hypertension. 
Bevacizumab should be permanently discontinued in patients 
Table 3 Current adjuvant studies utilizing bevacizumab in colorectal 
cancer
Adjuvant studies Chemotherapy regimen  n
AVANT74 FOLFOX-4 vs FOLFOX-4 plus 
bevacizumab vs XELOX plus 
bevacizumab
3450
NSABP C-0878 mFOLFOX6 with and without 
bevacizumab
2632
E 520276 FOLFOX with and without 
bevacizumab
3610
QUASAR 278 Capecitabine with and without 
bevacizumab
2240OncoTargets and Therapy 2009:2 9
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developing nephrotic syndrome.87–89 Nephrotic syndrome 
occurred in seven of 1459 (0.5%) patients receiving bevaci-
zumab in clinical studies. One patient died and one required 
dialysis. In three patients, proteinuria decreased in severity 
several months after discontinuation of bevacizumab.
Thromboembolism
Patients with malignancies are more prone to develop 
thromboembolic complications when compared to the 
normal population. Early phase II trials of bevacizumab in 
metastatic CRC showed a higher incidence of arterial throm-
boembolism (ATE) (5%) but not venous thromboembolism 
(VTE) (10%) compared with the control arm (3% and 9% 
respectively).57 In the pivotal phase III trial in patients with 
metastatic CRC evaluating the IFL regimen with and without 
bevacizumab, the incidence of all venous and ATE was 
19.4% versus 16.2% in the non-bevacizumab arm.9 It has 
been speculated that the blockade of the VEGF receptors 
leads to apoptosis of endothelial cells in the vasculature, 
thus exposing the subendothelial collagen and initiating 
a coagulation cascade resulting in an increased risk for 
thrombus formation.91
Analysis of pooled data from ﬁ  ve randomized trials in 
patients with metastatic CRC, breast, and non-small-cell 
lung cancer by Scappaticci et al showed increased risk of 
ATE (HR 2.0, 95% CI 1.05–3.75, p = 0.031) but not VTE 
(HR 0.89, 95% CI 0.66–1.20, p = 0.44).92 The absolute rate 
of developing an ATE was 5.5 events per 100 person-years 
for patients receiving combination therapy versus 3.1 events 
for patients receiving chemotherapy alone (ratio 1.8, 95% 
CI 0.94–3.33, p = 0.76). It was also noted that patients who 
do not use aspirin had a higher risk of developing ATE 
compared to the group taking aspirin (3.6% versus 1.2%). 
In the subgroup analysis, patients older then 65 years with 
previous history of ATE had a signiﬁ  cantly higher risk 
of developing ATE, if not taking concurrent aspirin with 
bevacizumab (22.9% versus 3.4%). The difference between 
older and younger than 65 years was not signiﬁ  cant in those 
receiving aspirin (12.5% versus 0%). In August 2004 the US 
Food and Drug Administration (FDA) sent a Dear Doctor 
letter to all US oncologists describing the increased rate 
of ATE in patients with prior events of ATE or patients 
aged   65 years during bevacizumab therapy.
Hambleton et al assessed the outcomes of patients 
with metastatic CRC who had a thrombotic event while 
receiving treatment with bevacizumab and remained on 
study with anticoagulation.93 Use of concomitant full-dose 
anticoagulation therapy with bevacizumab in combination 
with chemotherapy did not increase the risk of hemorrhagic 
complications in patients with metastatic CRC.
Analysis of thrombotic events in the BRiTE registry 
showed a similar risk of developing ATE in patients   65 years 
old compared with patients in the age group of 65 to 74 years 
(1.5%), though the rate was higher in patients older then 
75 years of age (4.1%).94
In summary, patients treated with bevacizumab are at 
a higher risk of developing ATE, especially patients older 
then 65 years with previous history of ATE.81,94,95 Although 
patients above 65 years have a slightly higher risk of ATE, 
oncologists must assess the risk/beneﬁ  t of its use, especially 
as the beneﬁ  t of bevacizumab is seen across all age groups. 
Use of prophylactic low-dose aspirin and treatment of VTE 
with full anticoagulation with warfarin appear safe.81,93 In 
patients who develop VTE on bevacizumab, bevacizumab 
should be on hold until the patient is fully anticoagulated; 
and in the event of any life-threatening VTE, bevacizumab 
should be discontinued. Patients who had a recent ATE 
(myocardial infarction, cerebrovascular event, transient 
ischemic attack) bevacizumab should not be initiated for at 
least 6 months. Bevacizumab should be started only once 
patient is stable, asymptomatic and after a detailed discussion 
of the risk involved. Patients who develop any ATE during 
bevacizumab therapy should be taken off treatment.87–89 
Patients who develop venous thromboembolism can be 
safely treated with anticoagulant therapy and there does not 
appear to be increased risk of bleeding with concomitant use 
of bevacizuamb.
As physicians gain more experience with bevacizumab 
and become familiar with patient selection, the risk of ATE 
associated with bevacizumab appears to decline. Appropri-
ately selected patients on E3200 and NO16966 studies with 
FOLFOX and bevacizumab experienced an ATE rate of 0.9% 
and 2%, respectively. These did not differ signiﬁ  cantly from 
the rates of their chemotherapy-only comparative arms of 
0.4% and 1%, respectively.55,56
Bleeding
Increased of bleeding was seen in patients with metastatic 
CRC treated with bevacizumab in early phase II studies.81 
The most signiﬁ  cant were gastrointestinal bleeding (6%) 
and the most common was self-limited epistaxis (46%). 
Bleeding from mucocutaneous membranes is common with 
bevacizumab and occurs in 20% to 40% of patients .This is 
mainly epistaxis and responds to usual ﬁ  rst aid techniques 
with cessation of most bleeding in less than 5 minutes. 
Bevacizumab should be discontinued in patients who need OncoTargets and Therapy 2009:2 11
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medical intervention. In randomized phase III studies grade 
3–4 bleeding was seen in 1.8% to 3.8% of patients (Table 5). 
This seems to be in line with the data presented from the 
BRiTE registry which reported serious bleeding events 
in 2.5% (49/1953) patients treated with bevacizumab and 
chemotherapy in metastatic CRC patients.96,97 The BRiTE 
study did not exclude patients on antiplatelet therapy(11.2%) 
and full dose anticoagulation (6.8%) and the authors con-
cluded that inclusion of these patients is relatively safe in 
terms of risk of serious bleeding complications. Patients with 
central nervous system metastasis are usually excluded from 
clinical trials, so incidence of CNS hemorrhage in patients 
with CNS metastasis is unclear.
Bevacizumab should not be initiated in patients with recent 
hemoptysis or CNS metastasis. Initiation of full dose anti-
coagulation appears to be safe in terms of risk of serious bleed-
ing events.81,93,96 Patients with congenital or acquired bleeding 
diathesis should be started on bevacizumab with caution.87,88
Surgical wound healing complications
Angiogenesis is an essential component of normal wound 
healing and VEGF inhibitors can delay angiogenesis in 
patients with cancer.98 Wound healing complications were 
analyzed in patients who underwent surgery within 28 to 
60 days of starting bevacizumab treatment and while on beva-
cizumab treatment in the study by Hurwitz et al.99 Patients 
who underwent surgery within 28 to 60 days of receiving 
bevacizumab with IFL or with 5-FU, had minimal increase 
in grade 3–4 wound healing/bleeding compared with the 
IFL-only group (10%, 6.8% and 0% respectively).99 Scap-
paticci et al assessed wound healing complications in patients 
with metastatic CRC who underwent cancer surgery 28 to 
60 days before treatment and in patients who underwent 
major surgery during treatment with 5-FU/LV with and 
without bevacizumab.100 Cases were reviewed for wound 
healing complications occurring   60 days after surgery. 
Increased wound healing complications were seen in patients 
who underwent surgery during bevacizumab therapy (13% 
versus 3.4%), but not in patients who received bevacizumab 
28 to 60 days post operatively (1.3% versus 0.5%). The 
wound complications included anastomotic wound dehis-
cence, ecchymosis and bleeding. Data from the BRiTE study 
showed an overall rate of serious wound healing complication 
as 3.7% (23/622), which was lower than the initial report in 
the pivotal by Hurwitz et al.101 Patients requiring surgery 
within 14 days of last bevacizumab dose had an increased risk 
of postoperative complications compared with patients who 
had surgery after 60 days (6.5% versus 1.8%).102 It is of note, 
however, that the implantation of a venous access device 
shortly before starting bevacizumab treatment does not seem 
to result in increased bleeding or other complications.103
In summary, patients who underwent surgery during or 
within 14 days of bevacizumab are at a higher risk of develop-
ing wound healing complications. Based on available data, bev-
acizumab should not be initiated within 30 days after surgery. 
Minor surgical procedures, such as insertion of venous access 
devices, can be done within 7 days of bevacizumab treatment. 
If patients have to undergo emergency surgery, bevacizumab 
should be held and patients should be followed closely for com-
plications. Elective surgeries should be planned 6 to 8 weeks 
after last dose of bevacizumab, though chemotherapy alone can 
be continued 2 to 3 weeks before surgery. Bevacizumab should 
be discontinued if any wound complication (ﬁ  stula, dehiscence) 
develops or if an intra-abdominal abscess develops.
Gastrointestinal (GI) perforation
The incidence of GI perforation is seen in 1.5% to 2.4% of 
metastatic CRC patients treated with bevacizumab and is 
associated with the highest bevacizumab-associated mortality 
(Table 5). The incidence of GI perforations appears to be 
higher in patients with intact primary tumor, prior adjuvant 
radiation therapy in rectal cancer, long-term nonsteroidal 
Table 5 Common terminology criteria for adverse events v3.0 (CTCAE)109
  Grade 1 Grade 2 Grade 3 Grade 4 Grade 5
Hypertension Asymptomatic, transient 
( 24 h) increase by 
 20 mmHg (diastolic) or 
to  150/100 if previously 
within normal limits
Recurrent or persistent 
( 24 h) or symptomatic 
increase by  20 mmHg 
(diastolic) or to  150/100 
if previously within normal 
limits
Requiring more then 
one drug or more 
intensive therapy than 
previously
Life-threatening 
consequences 
(hypertensive crisis)
Death
Proteinuria 1+ or 0.15–1.0 g/24 h 2+ to 3+ or  1.0–3.5 g/24 h 4+ or  3.5 g/24 h Nephrotic syndrome Death
Thrombo-embolism – DVT or cardiac thrombosis DVT or thrombosis Embolic event including 
PE or life-threatening 
thrombus
DeathOncoTargets and Therapy 2009:2 12
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anti-inﬂ  ammatory drug (NSAID) therapy ( 1 month of 
use), peptic ulcer disease, diverticulosis, and previous 
gastrointestinal surgery.9,104,105 Recently presented BRiTE 
registry data showed an incidence of GI perforation of 2.5% 
in patients  65 years, 1.5% in patients 65 to 74 years, 1.1% 
in patients  75 years old and 0.6% in patients  80 years 
old.94 In spite of surgery, treatment mortality rate remains 
high (12.5%–30%) for patients who develop GI perforation 
while receiving bevacizumab treatment.87,106
Patients with metastatic CRC who are treated with beva-
cizumab should be closely monitored for signs and symp-
toms of GI perforation, and radiographic imaging should be 
obtained immediately when clinically suspected. Patients 
with active peptic ulcer disease should be treated with either 
H2 blocker or proton pump inhibitors. Bevacizumab should 
be permanently discontinued in patients who develop GI 
perforation. Surgical intervention should be considered as 
and when appropriate.87,88 The manufacturer has issued a 
black box warning about the risk of GI perforation, wound 
dehiscence and fatal hemoptysis.
Reversible posterior leukoencephalopathy 
syndrome (RPLS)
RPLS has been reported in clinical studies (with an inci-
dence of  0.1%) and in postmarketing experience.87 RPLS 
is a neurological disorder which can present with headache, 
seizure, lethargy, confusion, blindness and other visual and 
neurologic disturbances. Mild to severe hypertension may be 
present, but is not necessary for diagnosis of RPLS. Magnetic 
resonance imaging is necessary to conﬁ  rm the diagnosis of 
RPLS.107,108 The onset of symptoms has been reported to 
occur from 16 hours to 1 year after initiation of bevacizumab. 
Discontinuation of bevacizumab and aggressive management 
of hypertension is indicated in patients developing RPLS. 
Symptoms usually resolve or improve within days, although 
some patients have experienced ongoing neurologic sequelae. 
The safety of reinitiating bevacizumab therapy in patients 
previously experiencing RPLS is not known.87
Conclusion
The integration of bevacizumab in the management of CRC has 
resulted in major improvement beneﬁ  ts in patients with meta-
static disease. In general, bevacizumab should be integrated 
with ﬁ  rst-line chemotherapy in patients with metastatic CRC, 
unless contraindicated. The continuation of bevacizumab 
beyond ﬁ  rst-line progression is still controversial, due to 
lack of prospective randomized evidence in this setting. 
The combination of anti-EGFR antibodies and bevacizumab 
with chemotherapy in metastatic CRC is currently contraindi-
cated outside a clinical trial setting. Older patients do beneﬁ  t 
from the addition of bevacizumab to chemotherapy, albeit 
with a slightly increased incidence of ATE.
Early results from adjuvant bevacizumab-based stud-
ies therapy of colon cancer do not show any signiﬁ  cantly 
increased risks. However, until supportive clinical efﬁ  cacy 
data become available in that setting, the use of bevacizumab 
should be considered investigational.
The recommended dosing of bevacizumab is 5 mg/kg 
every 2 weeks with FOLFOX/FOLFIRI-based regimens and 
7.5 mg/kg every 3 weeks with XELOX in the ﬁ  rst-line setting. 
Bevacizumab is generally well tolerated in combination with 
chemotherapy, without additive increase in chemotherapy-
related toxicities. However, bevacizumab-related adverse 
events such as HTN, proteinuria, perforation and ATE require 
extensive patient counseling and monitoring.
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